Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Active not recruiting 3

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3Dermatologic 1

Conditions

Melanoma 23Multiple Myeloma 9Colorectal Neoplasms 9Carcinoma, Non-Small-Cell Lung 9Glioma 8Thyroid Neoplasms 7Neoplasm Metastasis 7Hematologic Neoplasms 6Thyroid Carcinoma, Anaplastic 5Lymphoma 5Thyroid Cancer, Papillary 4Pancreatic Neoplasms 4Neurofibromatosis 1 4Neoplasms 4Lung Neoplasms 3Brain Neoplasms 3Astrocytoma 3Adenocarcinoma, Follicular 3Skin Neoplasms 2Recurrence 2Rectal Neoplasms 2Prostatic Neoplasms 2Ovarian Neoplasms 2Neurofibroma, Plexiform 2Leukemia, Myelomonocytic, Juvenile 2Histiocytosis, Langerhans-Cell 2Glioblastoma 2Colonic Neoplasms 2Advanced Solid Tumors 2Uveal Melanoma 1

Interventions

Radiosurgery 50Magnetic Resonance Spectroscopy 34Temozolomide 28Bevacizumab 24pembrolizumab 23Radiotherapy 20Nivolumab 20Specimen Handling 14Ipilimumab 13Cyclophosphamide 13Mental Status and Dementia Tests 12Carboplatin 12abemaciclib 10Radiation 10trastuzumab deruxtecan 8Proton Therapy 7Pemetrexed 7Memantine 7Blood Specimen Collection 7fluciclovine F-18 6binimetinib 6Paclitaxel 6Lomustine 6Etoposide 6Cisplatin 6Capecitabine 6encorafenib 5Trastuzumab 5Surveys and Questionnaires 5Surgical Procedures, Operative 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Brain Neoplasms × trametinib × 1 year × Clear all
NCT03363217 2026-04-24

Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.

St. Justine's Hospital

Phase 2 Active not recruiting
114 enrolled
CNS

Brain Neoplasms, Glioma, Neurofibromatosis 1, Neurofibroma, Plexiform

NCT02015117 2026-04-13

Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases

National Cancer Institute (NCI)

Phase 1 Active not recruiting
10 enrolled
CNS

Brain Neoplasms

NCT02910700 2025-12-17

Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
52 enrolled
CNSDermatologic

Brain Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡